Dr Bishr Omary, MD, PHD in Palo Alto, CA - General Acute Care Hospital

Dr Bishr Omary, MD, PHD is a General Acute Care Hospital - Critical Access physician based in Palo Alto, California. Dr Bishr Omary is licensed to practice in California (license number G058813) and his current practice location is 3801 Miranda Ave, Palo Alto Va Medical Center, Palo Alto, California. He can be reached at his office (for appointments etc.) via phone at (650) 493-5000.

NPI number for Dr Bishr Omary is 1649369844 and his current mailing address is 485 Emmons Dr, Mountain View, California. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1649369844.

Contact Information

	Dr Bishr Omary, MD, PHD
	3801 Miranda Ave, Palo Alto Va Medical Center, Palo Alto, CA 94304
	(650) 493-5000
	(650) 852-3259

Physician's Profile

Full Name	Dr Bishr Omary
Gender	Male
Speciality	General Acute Care Hospital - Critical Access
Location	3801 Miranda Ave, Palo Alto, California
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1649369844
Provider Enumeration Date: 10/12/2006
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Dr Bishr Omary such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1649369844	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207RG0100X	Internal Medicine - Gastroenterology	G058813 (California)	Primary
282NC0060X	General Acute Care Hospital - Critical Access	G058813 (California)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Bishr Omary is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Bishr Omary, MD, PHD 485 Emmons Dr, Mountain View, CA 94043-2726 Ph: (650) 493-5000	Dr Bishr Omary, MD, PHD 3801 Miranda Ave, Palo Alto Va Medical Center, Palo Alto, CA 94304 Ph: (650) 493-5000

News Archive

Researchers discover nature uses a recurring molecular strategy to defend against infection

With infections increasingly resistant to even the most modern antibiotics, researchers at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) report in the September issue of Nature Reviews Microbiology on new clues they have uncovered in immune system molecules that defend against infection.

New method to control inflammatory response induced by COVID-19

Severe COVID-19 illness can result in excessive inflammation throughout the body, including the lungs, heart and brain. University of Minnesota Twin Cities student Molly Gilligan recently published an article in the journal Cancer & Metastasis Reviews that studied the human body's robust inflammatory response to the SARS-CoV-2 virus, which is now recognized as a hallmark symptom.

UCLA researchers investigate how a protein factor contributes to cancer cell migration

UCLA researchers have discovered a new protein factor that contributes to a fibroblast cell's ability to migrate to a wound and participate in its healing process. The study's results could help scientists prevent cancer cells from using the same mechanisms to move throughout the body and spread.

Extract of broccoli sprouts may protect against bladder cancer

A concentrated extract of freeze dried broccoli sprouts cut development of bladder tumors in an animal model by more than half, according to a report in the March 1 issue of Cancer Research, a journal of the American Association for Cancer Research.

Trius commences oral torezolid phosphate Phase 3 clinical study for ABSSSI

Trius Therapeutics, Inc. announced that the first patient has been dosed in its Phase 3 clinical study of the oral dosage form of torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The double-blind, active control, pivotal study is designed to compare the efficacy and safety of once-daily oral administration of 200 milligrams of torezolid phosphate for six days of treatment with the efficacy and safety of twice-daily oral administration of 600 milligrams of linezolid (Zyvox®) for 10 days of treatment.

Dr Bishr Omary, MD, PHD - General Acute Care Hospital in Palo Alto, CA